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Abstract
Background: Decision aids (DA) to assist patients in evaluating treatment options and sharing in
decision making have proliferated in recent years. Most require high literacy and do not use plain
language principles. We describe one of the first attempts to design a decision aid using principles
from reading research and document design. The plain language DA prototype addressed
treatment decisions for localized prostate cancer. Evaluation assessed impact on knowledge,
decisions, and discussions with doctors in men newly diagnosed with prostate cancer.
Methods: Document development steps included preparing an evidence-based DA in standard
medical parlance, iteratively translating it to emphasize shared decision making and plain language
in three formats (booklet, Internet, and audio-tape). Scientific review of medical content was
integrated with expert health literacy review of document structure and design. Formative
evaluation methods included focus groups (n = 4) and survey of a new sample of men newly
diagnosed with prostate cancer (n = 60), compared with historical controls (n = 184).
Results: A transparent description of the development process and design elements is reported.
Formative evaluation among newly diagnosed prostate cancer patients found the DA to be clear
and useful in reaching a decision. Newly diagnosed patients reported more discussions with
doctors about treatment options, and showed increases in knowledge of side effects of radiation
therapy.
Conclusion: The plain language DA presenting medical evidence in text and numerical formats
appears acceptable and useful in decision-making about localized prostate cancer treatment.
Further testing should evaluate the impact of all three media on decisions made and quality of life
in the survivorship period, especially among very low literacy men.
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Background
Patients are increasingly urged to become involved in
treatment choices, including watchful waiting (surveil-
lance but no active treatment), by working through med-
ical evidence to decide on a course of action with their
physicians. Guidelines and evidence summaries are com-
monly available to physicians and frequently include a
"summary for patients", as do some major clinical jour-
nals. Decision aids have proliferated in recent years yet
most require high levels of literacy to access them and
have not been designed according to the principles of
plain language. This paper describes one of the first
attempts to make a decision aid accessible to consumers
with lower levels of literacy and education using princi-
ples from reading research and document design. To
develop a prototype plain language decision aid, and to
describe the design process, we designed a decision aid for
treatment decision making in localized prostate cancer.
Three standard therapies, surgery, radiation therapy, and
watchful waiting, are available to patients and paid for by
most insurers in the US. The 10-year mortality rate for
each of the standard treatments is equivalent, but the side
effects and the processes are quite different. This conun-
drum is made even more difficult because specialty physi-
cians tend to recommend treatments performed by their
own specialty [1,2]. Even inter-disciplinary case confer-
ences can expose patients to evidence and professional
opinions that appear to conflict.
The aim of the research reported here was to develop a
plain language decision aid for localized prostate cancer
initial management following a positive biopsy. Three
decision aids (booklet, Internet, and audio-tape formats)
were designed to contain equivalent information. Forma-
tive evaluation was designed to test acceptability to men
with both highly functional and limited literacy skills. We
wanted to make sure that the DAs were not perceived as
"dumbed down" either in tone or content. A further aim
was to identify missing information, and information that
might not adequately represent the cancer experience, The
aim was to include the perspective of community dwell-
ing men in the appropriate age group and men who had
had treatment for their prostate cancer.
Evidence-based patient choice
"Evidence-based patient choice" is a term coined by Hope
in 1996 and elaborated in a book by the same title [3] to
articulate the addition of the patient perspective to the evi-
dence based paradigm laid out by Sackett [4]. Adding
"patient choice" to evidence-based medicine is an effort to
locate the need for evidence squarely in a patient-centred
approach to patient-provider encounters. The theoretical
roots are in economics, ethics, psychology and medicine.
There are also political influences, including the con-
sumer choice movement and struggles over resource allo-
cation and health care organization. The synthesis of
ethical approaches to shared decision making, and
rational choice models provoke both theoretical and
political concerns, and is far from a perfect resolution. The
practical task of supporting patients' access to information
they can use led us to develop this new prototype. We also
desired to have the information available in real time to
reach the most satisfying resolution of treatment dilem-
mas. By making our assumptions transparent, and testing
the results with patients and scholars we hoped to
improve both theory and practice.
Approaches to evidence tools for patients
Decision aids exist in modest numbers, specific to partic-
ular clinical conditions. A recent meta-analysis identified
131 different decision aids across a variety of clinical
problems. Sixty-five of these fit the Cochrane criteria and
were evaluated in a randomized trial [5]. Decision aids
have expanded the scope of traditional patient education
materials and draw on several perspectives. These may be
classified conceptually as 1) traditional medical, 2) tech-
nology assessment (TA), and 3) patient-centred. Tradi-
tional patient education materials mirror the medical
model didactic elements. They include descriptions of: a)
the disease, b) its epidemiology, c) the morbidity and
mortality outcomes of the disease in the population, and
d) screening and treatment recommendations for either
public information campaigns or clinical encounters. This
model has been criticized for its emphasis on diseases,
rather than on patients and their concerns, and for being
paternalistic [6]. Decision aids have addressed the limita-
tions of the traditional medical approach by integrating
evidence-based medicine with patient choice and by
encouraging shared decision making. It has largely accom-
plished this with a technology assessment (TA) approach.
TA focuses on the quality of the medical evidence, levels
of rigor of evidence and providing symmetry in describing
risks and benefits of all patient options. The most widely
available examples of TA-based decision aids use the
Ottawa Decision Support Framework and BMJ Best Treat-
ments approach. The Ottawa Framework asks the deci-
sion-maker to choose among treatment or screening
choices demonstrated to be effective [7]. It emphasizes
clarifying values for outcomes and emphasizes weighing
the pros and cons of alternatives in the choice process to
arrive at a tentative choice that the patient discusses with
the physician. Consistent with evidenced-based health
care, it grades the medical evidence for each alternative
according to its quality. The Best Treatments approach
likewise grades the evidence, teaches patients about uncer-
tainty in data, but does not consistently provide numeri-
cal data for side effects [8]. The TA approach is a major
step forward in providing patients with accurate evidence
for making comparisons among alternatives, but it may
suffer from speaking to the professional health careBMC Medical Informatics and Decision Making 2005, 5:16 http://www.biomedcentral.com/1472-6947/5/16
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community better than it speaks to patients. To develop a
plain language prototype, we accepted most of the
premises of the TA approach, but redesigned the presenta-
tion of results, using plain language and document design
strategies.
Translation of evidence into plain language
The rationale for "re-constructing" decision aids in plain
language is that it works for patients with a wide range of
literacy abilities. Plain language includes three major ele-
ments: 1) The use of everyday language and other clear
writing strategies, 2) well-structured, logically sequenced,
and focused information, 3) effective design and layout. It
uses medical evidence as a base and attempts to lead read-
ers through the relevant elements to provide an opportu-
nity for synthesis and drawing conclusions about which
therapy best suits the values, fears and expectations of the
patient. A plain language approach incorporates social
marketing principles and is often used by pharmaceutical
companies, patient advocacy groups, and others to deliver
compelling messages. The materials these groups pro-
duce, however, sometimes minimize or eliminate num-
bers in the interest of being non-threatening and engaging
and accommodating limited quantitative literacy
skills[9,10].
Plain language approaches have also been used to com-
municate public health messages to patients. They fre-
quently attempt to persuade them to undertake an action
(e.g., engaging in cancer screening) rather than engage in
shared decision making. Highlighted by the recent Insti-
tute of Medicine report [11], many groups have published
plain language document design guidelines [12-17].
As stated by Hibbard and Peters [18], the challenge is
"how to present\ldotsinformation so that it is actually
used in decision making." They note that three informa-
tion presentation strategies assist consumers, all of which
are reflected in a plain language approach: lowering the
cognitive effort required to use information; linking infor-
mation to real-life situations to increase the emotional
connection; and presenting numbers in frequencies (e.g.
10 in 100). We addressed each of these in developing the
prostate cancer DA. To address the immediate world of
patients in the midst of being told of a disease and making
a decision, it is important to describe the relevant risks
and benefits of treatments without losing the precision
and realistic risk communication capacity of numbers.
Unpacking technical jargon actually adds substantial
detail about what will happen to the patient in non-tech-
nical, everyday terms. It also explains laboratory tests and
other medical information that doctors will use in making
recommendations. The purpose is to provide patients
with tools and encouragement to engage with the doctor
in discussing technical aspects of the information doctors
use to make a decision. Along with risk and benefit data,
a decision aid should also explain the treatment process to
the patient, in order that she or he can anticipate the per-
sonal experience of undergoing treatment. This approach
does not abandon or delete technical language. Rather it
defines it and provides examples, and phonetic pronunci-
ations of medical technical terms in order to improve
communication between patients and health
professionals.
In the prototype, we introduce the idea that there is varia-
bility among patients in their values for potential out-
comes. Unlike some decision aids that provide a rational
recommendation based on formal utility assessment [19],
this approach does not make a recommendation. The res-
olution of the values dilemma is left to patients, their fam-
ilies and friends, and health care providers.
Needs assessment
Prior to developing a new decision aid, we performed a
two-part needs assessment. In the first part, we searched
the literature for surveys providing information about
knowledge levels of newly diagnosed patients following
biopsy and discussion with their doctors but before treat-
ment. In the second part, we evaluated existing patient
education materials for localized prostate cancer. Since we
found no surveys of men actually facing the localized
prostate cancer treatment decision, we interviewed 184
men newly diagnosed with localized prostate cancer from
both community and tertiary care urology practices in
Michigan [20]. This sample served as the historical con-
trols for this paper. The survey included demographics,
patient knowledge about their prostate cancer, treatment
options, side effects and satisfaction with care. Bivariate
and multivariable analyses were performed to adjust for
potential confounding and to determine if sociodemo-
graphic factors affected understanding of key issues. Aver-
age age of the men was 64 years and 19% were African
American. Seventy-one percent completed some college
and 51% of patients were currently employed. White men
reported higher rates of knowing their PSA, stage and
grade (92%, 93% and 99% respectively) than African
American men (69%, 88% and 85%). Ninety-three per-
cent of all respondents stated that they had discussed
treatment options with a physician. Only 62% knew that
radical prostatectomy, external beam radiation therapy,
brachytherapy and watchful waiting were standard
options for localized prostate cancer. Significant associa-
tions between sociodemographic factors and a patient's
understanding of prostate cancer treatment issues were
identified. Despite objective gaps in knowledge, men
showed high satisfaction with information received from
their physicians.BMC Medical Informatics and Decision Making 2005, 5:16 http://www.biomedcentral.com/1472-6947/5/16
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Prostate cancer has been the subject of several decision
aids [21,22] Considerable research has identified patient
and health professional concerns about treatment. In part
2 of the needs assessment, we used our previously devel-
oped generic evidence template to provide evaluation
guidelines, but made it specific to prostate cancer [23]. We
used the template to comprehensively survey patient edu-
cation materials publicly available from US government
agencies, charities, drug companies and others for inclu-
sion or absence of the evidence elements. The full report
found key evidence to be missing from most patient edu-
cation materials (PEMs) [24]. We found that standard
treatment options were almost never explicitly compared
to one other. PEMs frequently did not describe the
chances of dying from prostate cancer or of experiencing
other side effects of each treatment. We found most did
not reflect consideration of the user in the way materials
were written, structured or designed. Finally, most did not
encourage patients to formulate a treatment preference to
discuss with their doctors.
Based on the needs assessment, we developed the decision
aid, described in this report, in three formats (booklet,
audio tape, and Internet) with particular attention to
Table 1: Information and Information Architecture Issues and Solutions
Concern Solution
Complex information • Organize and structure document for ease of understanding and use, 
including use of summary tables
• Create affective appeal using individual vignettes
• Describe all elements of treatment process patients experience
Engage the reader in the social context • Use pictures captioned with comments from men of varying ethnicities
• Suggest connection with trusted others and other patients
• Recognize and address feelings of fear
No mandatory autonomy • Suggest that decisions may be made by the patient or delegated to the 
doctor, or trusted individual.
• Suggest shared decision making is compatible with keeping or delegating
Anticipate cultural issues • African Americans are likely to be sensitive to potential to withhold 
treatment in the name of watchful waiting.
• African Americans frequently are diagnosed with more severe disease 
relative to whites.
• Sources of authoritative advice vary among ethnic groups. These can be 
acknowledged subtly in text
Translate medical words, but do not eliminate technical information • Define words and include a glossary
Creating/choosing appropriate pictures • Simplify anatomical drawings to include only necessary visual information
• Include realistic picture of torso, with head included to provide conceptual 
context
• Include photographs of men who look serious, but not devastated
Graphic Design and Layout: Use evidence-based document design 
principles
• Spacing to emphasize different points and topic changes
• Wide margins to make text less dense
• Adequate page size to keep information on a topic on one page
• Graphic design that draws the reader through the booklet
• Text design that keeps related information in close proximity
Plain language • Use conversational words and sentence structure, even if not standard 
grammar
• Keep the writing tight. Eliminate unnecessary words.
• Keep the tone friendly and personal, speaking directly to the reader.
• Explain technical language even though it adds words. Assumptions behind 
technical words must be included
• Make scientific references available on the website, but do not include in 
the textBMC Medical Informatics and Decision Making 2005, 5:16 http://www.biomedcentral.com/1472-6947/5/16
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plain language and to potential concerns of African Amer-
ican men. Three major challenges lay at the heart of the
plain language translation: 1) introducing the social and
emotional context, 2) translating the outcome and side
effect rates into plain language, and 3) encouraging
shared decision making. The three formats used the same
words and content organization to facilitate evaluation of
the impact of print, audio and Internet media on patient
knowledge and patients' assessment of the usefulness of
the different media in preparing to talk with the doctor.
Methods
The decision aid prototype: design method and 
assumptions
Based upon our earlier analysis of good and bad aspects of
the prostate cancer PEMs and an extensive search of the
clinical literature, a draft of the decision aid was prepared
in what might be called the standard medical parlance.
This material was iteratively modified to emphasize
shared decision making and incorporate the principles of
plain language. The research team who designed the
project was strongly guided at this point by two health lit-
eracy/plain language experts. Similarly, document design
and web design were strongly guided by graphics experts.
The prototype was presented to the Michigan Prostate
Cancer Action Committee (PCAC), a sub-committee of
the Michigan Cancer Consortium (MCC), a consortium of
hospitals, universities and cancer centrss in the State of
Michigan. Final edits were made based on the formative
evaluation by patients, clinicians, and the development
collaborators and the final document produced.
The prototype booklet and Internet version that resulted
from the evaluation process can be viewed at the Michigan
Cancer Consortium (MCC) website [25]. Table 1 lists the
design decisions made for the prostate cancer prototype.
Connecting to patients' social and emotional world
To connect with the concerns of men and their families
and friends about prostate cancer treatment, the decision
aids embed a number of emotional "hooks", showing
photographs of middle-aged men of varying races. Quotes
from different men state varying preferences for their pre-
ferred degree of autonomy: making the decision them-
selves, delegating it to family or the doctor, sharing it with
clergy, friends, or health professionals. These statements
are designed to legitimize a range of appropriate alterna-
tives for the problem of "who decides". They are meant to
avoid a "mandatory autonomy" position, allowing the
patient to hand off the decision to the physician if he does
not want to decide himself [26]. The central message pro-
motes active patient participation, followed by making,
sharing, or delegating the decision. Further, an attempt is
made to imbed in the text items that speak to culture-spe-
cific issues. For example, the statement is made that
watchful waiting does not mean that the doctor "just does
not want to treat me." This statement anticipates the com-
mon belief, particularly among African American patients,
that doctors may withhold treatment for cost or other
reasons.
The emotional context of the booklet is also invoked by
explicitly noting in the text that cancer is scary, and that
treatment side effects may have heavy emotional impact.
The emotional "threat" level of how the disease is dis-
cussed is planned to be at a moderate level. The decision
aid acknowledges inevitable fear, supplies concrete under-
standing of disease and treatment, and encourages a sense
that patients are competent to make the decision.
Presenting quantitative evidence
The goal of an evidence-based decision aid is to make the
information easy to read, remember, and use. The pros-
tate cancer prototypes use specific textual, organizational,
and design elements enhanced by appropriate message
framing. They do not assume the reader knows either the
technical meaning of words or the background context in
which they are used. This filling in of the "why" and "what
for" of laboratory tests, treatment regimens, and other
medical information is essential for the millions of adults
with limited literacy skills and limited experience with
navigating the medical system. It is also preferred by most
people when learning new information, especially in a
highly charged emotional context. Specific guidelines for
the prostate cancer decision aids were: 1) aim for low to
average reading level (grade 7 level), 2) present quantita-
tive risk information as simply as possible, both positively
and negatively framed [27], and 3) use a minimum of
technical medical terms, and provide a glossary, called
"explanation of medical terms". The objective is to invite
all patients to grapple with the decisions they face with as
little intervening struggle with technical medical language
as possible. The result, ideally, is sophisticated ideas in
plain language.
To invite the patient into the content requires attention to
"information architecture" and the layout of information
on pages to guide the reader through the text. Thus, the
density of information on a page, the choice of a booklet
or an electronic tool, and the length and "feel" of the
information tool become important. The organizing prin-
ciple was to describe each treatment option in a complete
synopsis on its own on two facing pages of the booklet, or
on sequential web pages under one button. The audiotape
is organized in "chapters", like a "book on tape". For each
treatment, the text describes, "What happens", "How this
treatment can help", and "How this treatment may cause
problems." Each of the individual synopses tells the
whole story about a specific treatment. The treatment
options are followed by two comparison tables, one nar-BMC Medical Informatics and Decision Making 2005, 5:16 http://www.biomedcentral.com/1472-6947/5/16
Page 6 of 11
(page number not for citation purposes)
rative and one quantitative. The summary tables explicitly
compare results across treatments. Very brief directions
guide the reader in how to use the tables. Additional infor-
mation, not related explicitly to the choice (stage and
grade of cancer, and PSA tests), is described in the same
amount of detail as a single treatment option (two facing
booklet pages). The objective is to demystify what will
happen, show how doctors decide what is best, describe
the degree of uncertainty about test outcomes, and indi-
cate the medical information on which decisions are
based.
Side effects and mortality are presented as mean values,
not including the ranges. This is a pragmatic solution to
the simplification task, and should be tested further.
Explaining that diagnostic test results are imperfect infor-
mation, and that treatments have only a probability of
success is a new idea to most patients. The design task was
to present uncertainty, but keep it simple. Another quan-
titative principle that is critical to informed consent is
presentation of absolute, rather than relative risks in terms
of specifying a number out of 100 rather than a percent-
age. Absolute rates have been demonstrated to provide
patients with improved estimates of their own chances of
experiencing a particular outcome [28].
Shared decision making
A third challenge was to encourage shared decision mak-
ing without specifying the form of the clinician-patient
conversation or the values discussion. The message on the
cover of the DA first introduces the concept of choice, that
"there is no right answer" to this treatment problem. The
general statement, "Your treatment decision is a shared
one between you and your doctor" is later stated directly.
A "things to think about" section at the end of the booklet
asks a patient to identify his most important goal for treat-
ment, such as curing cancer, ameliorating symptoms, hav-
ing the best possible sexual performance, or good bowel
and bladder control. Patients are also asked to write down
the best and worst thing for them about each treatment
option. These sections are designed to facilitate an open
discussion with the physician without directing it.
The booklet was provided to each person with a request to
provide written or verbal feedback. The booklet form of
the decision aid was finished first, and provided the text
and order of presentation that were duplicated in the
audiotape and Internet versions. Qualitative methods
were used to evaluate and revise the booklet before survey
testing was performed with a new sample of men newly
diagnosed with prostate cancer.
Results
Formative evaluation
Evaluation was performed in two phases. Phase 1 was a
focus group evaluation of the draft language. Phase 2 was
a survey follow-up of 60 men newly diagnosed with pros-
tate cancer, using the DA in real-time decision making.
The Michigan State University and University of Michigan
human subjects IRBs approved all study materials and
procedures. Verbal and written consent for participation
was obtained at the beginning of interviews and patient
encounters.
Phase 1: focus groups
Design and procedure
Focus group methods were used to identify unacceptable
or confusing language and to identify missing informa-
tion or information needed to fully represent the impor-
tant issues for decision making. This information was
obtained from the perspective of men who had not expe-
rienced prostate cancer, and also those who had. The ana-
lytic techniques used were similar to ethnographic
techniques, although cross-sectional rather than longitu-
dinal qualitative reports were used [29].
Homogeneous groups by race were formed to encourage
participants to feel comfortable and to express concerns
about bias. A moderator's guide addressed the acceptabil-
ity of content and language, perceived understandability,
and usability of the format. We inquired specifically about
text passages that described risk numbers, results of a ran-
domized clinical trial, the meaning of laboratory tests and
their implications for mortality and treatment. Open-
ended questions asked men their perception of the DA
main message.
Four focus groups were conducted. Each session lasted
between 1.5 and 2 hours and was facilitated by a physi-
cian. Booklets were mailed to participants two weeks prior
to the focus group and participants were encouraged to
review the booklet in detail to provide feedback during
the focus group session. Confidentiality ground rules were
established and agreed upon by participants. After the ses-
sion, a twenty-five dollar honorarium was provided to
compensate participants for time and travel. Immediately
following participants' departure, a debriefing session was
held between the facilitator and assistant to develop and
amend observation notes and record suggestions for sub-
sequent focus groups. All focus groups were tape-
recorded.
Sample
Post-treatment men who had undergone surgery or radia-
tion therapy for prostate cancer were recruited from a ter-
tiary care prostate cancer clinic. Community men at risk
for prostate cancer due to age were recruited from a studyBMC Medical Informatics and Decision Making 2005, 5:16 http://www.biomedcentral.com/1472-6947/5/16
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of decision making in benign prostatic hyperplasia. Actual
patients at the point of decision making were not included
in the focus group, due to their potential vulnerability to
inaccurate, misleading, or offensive content. Twenty-five
men participated in four focus groups. Mean age was 64.5
years (range 49–80). Twenty-four had health insurance;
approximately half were not college educated.
Focus group results
The men found the prototype booklet "encouraging" and
"comforting." The general consensus was that prostate
cancer appeared to be something "that can be dealt with."
The DA was described as "professional," the "right size" (8
1/2 × 11), and containing the right balance between the
size of white space and of print. The summary table of
treatments and risks and the comparison table were
viewed as especially helpful and men stated that these
clarified individual treatment descriptions. The level of
detail was described as being "just right", with the excep-
tion that the decision aid did not include detailed descrip-
tion of non-standard treatments (cryosurgery and nerve-
sparing surgery). These were added, as was a recom-
mended diagram showing cancer spreading to the sur-
rounding lymph nodes and nerves.
Positive and negative framing of statistical information
The booklet stated each side effect as both a number out
of 100 chance of occurrence and that number subtracted
from 100 as the chance of avoiding occurrence. However,
the obvious redundancy was interpreted by some readers
as talking down to them and insulting their intelligence.
To make it less repetitive, the wording was changed to vary
the outcome named and acknowledge that this was
another way of stating the outcome. Table 2 shows major
changes made based on feedback.
Perspectives of African American men vs. White men
While all found the booklet professional and a good
source of information, there were differences in what
issues the groups discussed. For African American men,
the multicultural photos were important in that they illus-
trated that prostate cancer affects men of any race. The par-
ticipants did suggest inclusion of more specific mortality
information by race. (See Table 2).
African American men discussed several aspects of fear,
including fear about acknowledging health problems, and
the absence of fear in the faces of the men in the photos.
They characterized the overall message of the booklet as
not to be afraid. They also cited fear and distrust as major
obstacles preventing their acknowledging a health prob-
lem. African American men did not feel the text talked
down to them and felt the words were manageable –
"there are no big words in this booklet." One commented
that, "I didn't feel like you were treating me like a 3rd
grader." Lastly, the African American men read the overall
Table 2: Booklet Improvements based on formative evaluation
Information item identified in focus 
groups and approved by investigators
Draft 1 Draft 2
Emotional impact None Hearing that you have prostate cancer may 
shock or frighten you, your family, and your 
friends. These feelings are natural. They may 
change over time, as you learn about your 
diagnosis, make treatment decisions, deal with 
symptoms, and go on with your life. Men are 
often afraid to share their feelings or get help 
from a counselor if needed. If strong feelings 
are hurting you or your family, ask your doctor 
to suggest help.
Positive and negative framing "If 45 men out of 100 experience impotence, 
this means that 55 do not."
"...about 45 men out of 100 have permanent 
impotence. This means that 55 men out of 100 
will have their original level of sexual activity."
African American differences None "African American men are often diagnosed at 
a younger age than white men and with more 
advanced prostate cancer. However, treatment 
may be equally successful for both groups if 
given the same care."
Specific drug name, "like Viagra" "medicine that helps with erections"
Treatment detail No mention of cryosurgery or nerve-sparing 
surgery
Included under "newer treatments".
Drawing Three inset pictures Only two
Watchful Waiting description Few disadvantages listed Added disadvantages regarding potential 
progression of diseaseBMC Medical Informatics and Decision Making 2005, 5:16 http://www.biomedcentral.com/1472-6947/5/16
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message of the booklet as one of "don't be afraid,"
whereas the White men read the message as one of
"informed decision making". Several men across groups
commented that they rarely read health related materials,
but that they read every word before coming to the focus
group. "I normally only read sports. But I read this straight
through".
Post-treatment men vs. community men
Men who had been treated for their prostate cancer
appeared to find discussing the DA more difficult than did
the men of the same age who did not have prostate cancer.
While they appreciated the information, some indicated
that they were not convinced that they really had a choice
when deciding on actual therapy, either because of the
doctor's presentation or their own concerns about cancer.
They also indicated that the consequences of the treat-
ment decision were more emotionally difficult than they
anticipated. These men appeared to struggle with the
emotional and psychological consequences of their own
treatment decisions. Post-treatment White men suggested
that the emotional impact of treatment be more strongly
addressed as illustrated by the following comments:
"But this doesn't deal with... your first issue is to stay alive
and the second issue is the quality of your life afterwards
and that may be whether you are incontinent or maybe
whether you don't have erections.....But to the fact that,
uh, you need to talk to your surgeon about the psycholog-
ical consequences of the expected outcome of this surgery.
Maybe you only think about living first, but looking at it
in retrospect, I was like.... Whoa, why didn't you tell me
that ahead of time? Not that I would have made a different
decision. I just want to be well informed. I didn't get that".
Some post-treatment men felt that the booklet was biased
toward watchful waiting as a treatment choice. This was
addressed by adding specific negative aspects to watchful
waiting in the summary.
For example:
"But this book, uh, had in mind a definite cast toward
watchful waiting as opposed to more active interventions
and I agree that, uh, that in fact for many of us that was
not a very viable option I mean intellectually or emotion-
ally or whatever" and "But as I said before, I thought there
was a subliminal message there that said that watchful
waiting was probably a preferred choice."
Phase 2: survey
To test the usefulness of the revised decision aid to men at
the point of decision, a new convenience sample of 60
men newly diagnosed with prostate cancer on the basis of
biopsy was recruited to test the usefulness and influence
of the DA in real-time decision making. Participants were
recruited and provided a decision aid after receiving their
prostate cancer diagnosis at a post-biopsy visit to their
urologists. The urologist introduced a research assistant to
patients at the end of the visit in which he was told of his
cancer diagnosis. The patient was asked if they would like
to be in a research study evaluating the effectiveness of the
three different decision tool formats. Patients were
recruited sequentially until 20 had been accrued to use the
booklet. After the Internet and audiotapes were devel-
oped, 40 additional patients were recruited to evaluate
these formats. Due to the necessity for computer access for
use of the Internet version, these men were offered a
choice of the audiotape or Internet decision aid until 20
men were recruited for Internet and 20 for audio-tape use.
A telephone survey lasting approximately 20 minutes was
conducted by trained survey researchers from the Institute
for Public Policy and Social Research of Michigan State
University.
The survey included knowledge items taken from the pre-
vious needs assessment. DA evaluation questions assess-
ing balance, clarity, and length of the DA were modeled
after those of Barry et. al. [30]. Demographic (age, race,
income, education and geography) and disease (prostate
specific antigen (PSA), cancer stage, and grade) character-
istics were ascertained during the interview. Knowledge
questions included knowing one's own test results (PSA,
stage, grade), treatment options and side effects.
Sample
The sample of 60 men recently diagnosed with prostate
cancer had an average age of 62 years (SD = 7.9). Ninety
percent reported their race as White (8% as African Amer-
ican), 5% had not graduated from high school, 20% had
a high school dipoloma or GED, 32% had some college
training, 19% had received a bachelors degree and 24%
had received training post-baccalaureate. Sixty percent
were employed, 33% were retired, and 5% were unable to
work. Twenty-two percent had an income of less than
$25,000 and 77% reported Internet access.
Survey results
The responses of men using the three different media
(internet, audio, booklet) were virtually identical across
all survey items with the exception that those receiving the
audio version were less likely to share it with family and
friends (data not shown). Table 3 shows that the sample
of men utilizing the DA and historical controls had simi-
lar knowledge of their own pathology results, with the
exception that the DA sample were less likely to be
informed of the stage of their cancer (Fisher's Exact Test P-
value = 0.003). Knowledge of treatment options was not
significantly different between the two groups. However,
12% more men believed watchful waiting to be a standardBMC Medical Informatics and Decision Making 2005, 5:16 http://www.biomedcentral.com/1472-6947/5/16
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treatment in the DA group (87% vs 75% in controls, p =
0.073). In addition, 6% fewer men believed external
beam radiation to be a standard treatment in the DA
group (88% vs 94% in controls, p = 0.159).
Discussion of treatment options with the physician
showed a significant increase in surgery discussions (98%
in DA group, 89% in controls, p = 0.019). Discussions of
watchful waiting increased by 6% to 47% in the DA
Table 3: Knowledge: DA sample vs. historical controls
DA sample
(N = 60)
Historical controls
(No./Total)
Fisher's Exact 
Test P-value
Knowledge of personal pathology results
Knew PSA 56 (93%) 160/181 (88%) 0.34
Informed of stage of cancer 53 (88%) 178/181 (98%) 0.00
Knew grade of cancer 57 (95%) 178/184 (97%) 0.69
Knowledge of treatment options
Knew all of age, grade, stage, health, and PSA are at least somewhat 
important for treatment decision.
52 (87%) 142/184 (77%) 0.14
Believed watchful waiting to be a standard treatment 52 (87%) 138/184 (75%) 0.07
Believed external radiation to be a standard treatment 53 (88%) 173/184 (94%) 0.16
Believed brachytherapy to be a standard treatment 47 (78%) 143/184 (78%) >0.99
Believed surgery to be a standard treatment 57 (95%) 177/184 (96%) 0.71
Discussed watchful waiting with physician 28 (47%) 72/184 (39%) 0.36
Discussed external radiation with physician 53 (88%) 166/184 (90%) 0.63
Discussed brachytherapy with physician 38 (63%) 121/184 (66%) 0.76
Discussed surgery with physician 59 (98%) 163/184 (89%) 0.02
Knowledge of side effects
Knew surgery associated with incontinence 59 (98%) 172/184 (93%) 0.20
Knew surgery associated with impotence 58 (97%) 172/184 (93%) 0.53
Knew surgery associated with painful bowel movements 33 (55%) 82/184 (45%) 0.18
Knew radiation associated with incontinence 48 (80%) 113/184 (61%) 0.01
Knew radiation associated with impotence 56 (93%) 145/183 (79%) 0.01
Knew radiation associated with painful bowel movements 46 (77%) 118/184 (64%) 0.08
Table 4: Clarity and usefulness of DA (n = 60)
Amount of 
information
Much less than 
needed 5%
A little less than 
needed 14%
About right 77% A little more than 
needed 4%
DK or refused 7%
Length Much too short 
0%
A little too short 
11%
About right 84% A little too long 
5%
DK or refused 5%
Clarity of words All clear 44% Mostly clear 51% Some clear/ not 
5%
Most unclear 0% All unclear 0% DK or refused 2%
Difficulty of 
numbers
Very easy 64% Somewhat Easy 
24%
Somewhat 
difficult 12%
Very difficult 0% DK or refused 3%
Treatment 
description balance
Complete balance 
80%
Slanted to surgery 
9%
Slanted to 
radiation 4%
Slanted to WW 
7%
DK or refused 8%
Recommend DA to 
a friend?
Definitely would 
78%
Probably would 
20%
Unsure 0% Probably would 
not 0%
Definitely Would 
not 2%
DK or refused 2%
DA improved 
understanding
Definitely did 49% Probably did 42% Unsure 2% Probably did not 
2%
Definitely did not 
5%
DK or refused 2%
Numbers influenced 
my decision
Definitely did 12% Probably did 41% Unsure 2% Probably did not 
22%
Definitely did not 
22%
DK or refused 3%
DA helped decision 
making
A lot 14% Quite a bit 30% Moderate 32% A little 16% Not at all 9% DK or refused 5%
DK = Don't knowBMC Medical Informatics and Decision Making 2005, 5:16 http://www.biomedcentral.com/1472-6947/5/16
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group, and discussions of radiation decreased by 2%
(external beam) and 3% (brachytherapy). While not sig-
nificant, and very small, these changes are consistent with
the increase in knowledge of options and side effects.
Table 4 shows that the DA was universally found to be
clear and helpful. A substantial percentage of men
reported that the DA influenced their decision making.
Eight-six percent of men reported that they shared the DA
with a spouse or partner; 22% shared it with other family
members; 14% shared the DA with friends. Seventy-two
percent reported that they were more likely to take an
active role in their treatment decision.
Discussion
This attempt to marry evidence-based shared decision
making and plain language appears to have been inform-
ative and helpful in decision making among a diverse set
of men. The design process we used was found to translate
medical language while retaining quantitative informa-
tion. The resulting DA was almost universally found to be
helpful in decision making. Men in the DA group were
more likely to discuss surgery with their physicians and to
know that radiation therapy has side effects. Men reported
sharing the DA with family and reported that the DA
increased the likelihood of taking an active role in deci-
sion-making with the physician. The comparisons
reported are limited by the use of historical controls and
by the unavailability of data about actual decisions made.
However, the two cohorts were surveyed using exactly the
same questions. Both cohorts were very well informed
about their own test results and about side effects of sur-
gery. Side effects of radiation where less well known and
somewhat responsive to the decision aid.
In qualitative analyses, patients identified several princi-
ples of the plain language approach as particularly impor-
tant to them. Those included "translations" of medical
language, the emotional difficulties of choices, and the
use of what they called attractive layout and illustrations.
Some men objected to numbers shown both as a percent-
age and 100 minus that percentage to rigorously frame
each in both positive and negative. However, the provi-
sion of numbers to show frequency of side effects of treat-
ments was considered essential. We did not find that
patients perceived plain language as "talking down".
It is important to ask what is gained and what is lost in
translating evidence-based TA approaches to plain lan-
guage. Decision aids have been demonstrated to improve
knowledge and assist patients in coming to stable deci-
sions earlier in the treatment process [31,32]. In the face
of that success, what improvements in decision aid effec-
tiveness may be expected with the plain language integra-
tion and what may be lost? The major deletion we have
made from the TA approach is the grading of the medical
evidence studies used as source material. We presented
rates of outcomes but did not indicate whether they came
from randomized clinical trials or descriptive studies. Our
reasoning is that grading actually distracts from the simple
presentation of rates of mortality and side effects of
treatments, and that absorbing what the rates mean is the
core of what is needed to make an informed choice. Ref-
erences were made available separately.
Health literacy research shows that even highly educated
patients who are worried and stressed by a difficult health
decision prefer simple, every-day language that is easy to
read quickly. No patients asked for references. The credi-
bility of the DA may have been enhanced by their physi-
cian's offering it to them and by the endorsement of the
Michigan Cancer Consortium (MCC). MCC represents
major research universities, the State health department,
and 75 other major Michigan medical organizations.
Conclusion
The plain language DA presenting medical evidence in
text and numerical formats appears acceptable and useful
in decision-making about localized prostate cancer treat-
ment. The gains lie in the potential to improve on earlier
gains in patient knowledge. If the actual content is not
diluted, but the language, organization and design are
more useful for patients, it is possible that mean knowl-
edge scores may improve and that the median and the
mean will converge. Parker et al [9] argue that health liter-
acy is central to multiple health system priorities, includ-
ing quality, cost containment, safety, and patients'
involvement in health care decisions. They suggest that
without attention to literacy, the move toward increased
patient participation in health care decisions will exacer-
bate disparities in access and outcomes. This could mean
that people with poor health literacy cannot function suc-
cessfully in an environment designed for active, informed
consumers. It should be noted that among our historical
controls, there were large and significant deficits in knowl-
edge among African Americans compared with White
patients. We did not have sufficient numbers of African
Americans in the intervention sample to test the ability of
the DA to improve this deficit or to gauge the effect the DA
had on willingness to discuss treatment options with phy-
sicians. Further testing should evaluate the DA among
men with historically low levels or information, as well as
among very low literacy men and non-readers. Testing of
this DA in a trial against usual care is needed, as is devel-
opment of the plain language approach in other
conditions.BMC Medical Informatics and Decision Making 2005, 5:16 http://www.biomedcentral.com/1472-6947/5/16
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